Start-up plans to target epilepsy using gut microbiota
Bloom Science plans to have its proprietary gut bacteria in the clinic for hard-to-treat patients in the next 12-18 months.
Bloom Science plans to have its proprietary gut bacteria in the clinic for hard-to-treat patients in the next 12-18 months.
By passively collecting seizure data, Empatica's device could help patients share medical information with clinicians and make that data easier to manage.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Medical researchers frequently spend the majority of their time formatting research data and 10 percent of their time actually using it. Blackfynn hopes its platform will aid translational research and therapeutic product development.
NeuroVice's device is designed to provide a safe way to protect tongues and minimize salivation during seizures.
The goal is to track the severity and length of the seizure using sensors such as an accelerometer and a gyroscope as well as a memory test when the user comes out of the event.
Aprecia Pharmaceuticals is getting closer to commercializing SPRITAM, its 3D printed formulation of levetiracetam, which is a well-established medication used by patients with epilepsy.
The day after news broke that Turing Pharmaceuticals' Daraprim has a new competitor on the market, CEO Martin Shkreli announced the company's gotten fast-track status for its experimental epilepsy drug.
Turing isn't just buying drugs and bumping up prices. It is actually putting a focus on new drugs, which is exemplified with its recent investigational new drug application.
The Los Angeles-based company developing its drug-resistant epilepsy system has officially backed out of its IPO plans.
New, wearable technology not only helps monitor symptoms automatically, it may be able to predict seizures and disease progression in patients with neurological disorders.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
The FDA just approved the first 3D printed drug. Are there other applications for this technology?
The FDA has approved a 3D-printed drug designed to treat epileptics, OraSure Technologies' Ebola test gets emergency use authorization.
Here’s a story with a slight Cyborg ring to it: An implantable brain device that can potentially restore the memory of patients with traumatic brain injury, Alzheimer’s disease, epilepsy and related conditions is being developed at the government’s Lawrence Livermore National Laboratory. The technology sits at the nexus of human, neuron-based memory and digital, computer chip-based memory: The device […]
It’s easier to help a person having an epileptic seizure in the well-lit daytime as opposed to the pitch-black night. That’s the problem the SAMi monitor is changing. SAMi founders Cynthia and Charles Anderson created the device to help monitor the seizures their son was having at night. Charles, who is an engineer, developed the […]
We just talked about how to move digital health beyond the healthiest people in the room. Many of the wearable companies who have survived to this round of the Wearables Sweet 16 are doing just that. Instead of tracking steps taken or floors climbed, these companies are aiming to diagnose breast cancer sooner, increase access […]